natgillin/translations-raw huggingface dataset:
The process of claim 1, wherein said PSA adsorbs at a temperature of at least 150°C and a pressure of at least 5516 kPa (800 psia). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeni PSA adsorbira na temperaturi od najmanje 150 °C i pod tlakom od najmanje 5516 kPa (800 psia).
An apparatus of decoding video data in a merge mode, wherein, in merge mode, motion information of one of merge candidate blocks is set to motion information of a current prediction unit, comprising: 
Postupak dekodiranja video podataka u režimu spajanja, gdje se, u režimu spajanja, informacije o pokretu iz jednog od kandidata blokova za spajanje postavljaju kao informacije o pokretu tekuće predikcijske jedinice, što sadrži:
The apparatus of claim 1, wherein a reference picture index of the temporal merge candidate is set as 0. 
Postupak prema Zahtjevu 1, gdje se indeks referentne slike kandidata za vremensko spajanje postavlja na nulu.
The apparatus of claim 1, wherein a motion vector of the temporal merge candidate is a motion vector of a temporal merge candidate block within a temporal merge candidate picture, and a position of the temporal merge candidate block is determined based on a position of the current block within a largest coding unit (LCU). 
Postupak prema Zahtjevu 1, gdje je vektor pokreta kandidata za vremensko spajanje vektor pokreta kandidata bloka za vremensko spajanje unutar kandidat slike za vremensko spajanje, i gdje se pozicija kandidata bloka za vremensko spajanje određuje na osnovu pozicije tekućeg bloka unutar najveće jedinice kodiranja (LCU).
The apparatus of claim 4, wherein the motion vector of the temporal merge candidate is a motion vector of a motion vector storing unit corresponding to the position of the temporal merge candidate block. 
Postupak prema Zahtjevu 4, gdje je vektor pokreta kandidata bloka za vremensko spajanje vektor pokreta iz jedinice za čuvanje vektora pokreta koja odgovara poziciji kandidata bloka za vremensko spajanje.
The pharmaceutical composition of claim 1, wherein the buffer is a phosphate or acetate buffer. 
Farmaceutska kompozicija iz patentnog zahtjeva 1 ili patentnog zahtjeva 2, gdje je pufer fosfatni ili acetatni pufer.
The pharmaceutical composition of claim 1, further comprising a stabilizing agent. 
Farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 1-3, koja dodatno sadrži agens za stabilizaciju.
The pharmaceutical composition of claim 1 for use in the treatment of heart failure. 
Farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 1-10 za primjenu u liječenju srčane insuficijencije.
The pharmaceutical composition of claim 1 for use in the treatment of acute decompensated heart failure. 
Farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 1-10 za primjenu u liječenju akutne dekompenzirane srčane insuficijencije.
The pharmaceutical composition of any one of claims 1 and 2, wherein said composition comprises at least one viscosity-increasing agent selected from the group consisting of a polyvinylpyrrolidone, hydroxyethyl cellulose, carboxymethyl cellulose, hypromellose, carrageenan, guar gum, an alginate, a carbomer, a polyethylene glycol, a polyvinyl alcohol and xanthan gum that reduces or prevents postnasal drip of said composition into the pharynx upon intranasal administration of said composition. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što navedeni pripravak sadrži najmanje jedno sredstvo za povećavanje viskoznosti, koje se bira iz skupine koju čine polivinilpirolidon, celulozni derivat, kojeg se bira iz skupine koju čine hidroksietilceluloza, karboksimetilceluloza i hipromeloza, karagenan, guar guma, alginat, karbomer, polietilen-glikol, polivinil-alkohol i ksantanska guma, koje smanjuje ili sprječava postnazalno cijeđenje navedenog pripravka u ždrijelo prilikom intranazalne ili okularne primjene pripravka.
A pharmaceutical composition for use in reducing IL-6 for the treatment of cancer in a subject, wherein the composition comprises a therapeutically effective amount of at least one compound of Formula I: or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein: 
Farmaceutski sastav, naznačen time, da se upotrebljava u smanjivanju IL-6 za liječenje raka kod pojedinca, pri čemu sastav obuhvaća terapeutski učinkovitu količinu najmanje jednog spoja formule I:
Rb2 and Rb6 are independently selected from hydrogen, methyl and fluorine; 
Rb2 i Rb6su neovisno odabrani od sljedećih: vodik, metil i fluor;
Rb3 and Rb5 are independently selected from hydrogen, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, and C1-C6 alkoxy; and Rb2 and Rb3 and/or Rb5 and Rb6 may be connected to form a cycloalkyl or a heterocycle, provided that at least one of Ra1, Ra2, Ra3, and Ra4 is not hydrogen. 
Rb3 i Rb5su neovisno odabrani od sljedećih: vodik, halogen, C1-C6 alkil, C3-C6 cikloalkil i C1-C6 alkoksi; i Rb2 i Rb3i/ili Rb5 i Rb6mogu biti spojeni za tvorbu cikloalkila ili heterocikla, uz uvjet da najmanje jedan od Ra1, Ra2, Ra3 i Ra4nije vodik.
Rb2 and Rb6 are independently selected from hydrogen, methyl, and fluoride; 
Rb2 i Rb6su neovisno odabrani od sljedećih: vodik, metil i fluor;
The pharmaceutical composition for use according to claim 2, wherein: 
Farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da: U je C=O;
The pharmaceutical composition for use according to claim 2, wherein Ra1 is selected from hydrogen, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, and halogen. 
Farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da je Ra1 odabran od sljedećih: vodik, nesupstituirani C1-C6 alkil, nesupstituirani C1-C6 alkoksi i halogen.
The pharmaceutical composition for use according to claim 2, wherein Ra2 is selected from hydrogen, C1-C6 alkyl substituted with heterocyclyl, unsubstituted C1-C6 alkoxy, amino, and heterocycle. 
Farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da je Ra2 odabran od sljedećih: vodik, C1-C6 alkil supstituiran s heterociklom, nesupstituirani C1-C6 alkoksi, amino i heterocikl.
The pharmaceutical composition for use according to claim 2, wherein Ra4 is selected from hydrogen, unsubstituted C1-C6 alkoxy, and halogen; 
Farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da je Ra4 odabran od sljedećih: vodik, nesupstituirani C1-C6 alkoksi i halogen.
The pharmaceutical composition for use according to claim 2, wherein Rb3 and Rb5 are independently selected from hydrogen, methyl, C1-C6 alkyl substituted with heterocyclyl, and unsubstituted C1-C6 alkoxy wherein Rb2 and Rb3 and/or Rb5 and Rb6 may be connected to form a phenyl ring. 
Farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da su Rb3 i Rb5 neovisno odabrani od sljedećih: vodik, metil, C1-C6 alkil supstituiran s heterociklom, i nesupstituirani C1-C6 alkoksi, gdje Rb2 i Rb3 i/ili Rb5 i Rb6mogu biti spojeni za tvorbu fenilnog prstena.
The pharmaceutical composition for use according to claim 1, wherein the compound is selected from: 
Farmaceutski sastav za uporabu prema zahtjevu 1, naznačen time, da je spoj odabran od sljedećih:
fifth - separation phase by sedimentation; and sixth - advanced oxidation phase with simultaneous ozonation and ultraviolet irradiation treatment; or filtering phase through sand and activated carbon filters. 
peta - faza separacije sedimentacijom; i šesta – napredna oksidacijska faza uz istodobnu ozonaciju i ultraljubičasto zračenje; ili fazu filtriranja kroz pijesak i filtere aktivnog ugljena.
Process according to claim 1, wherein mixing in the first and second reactor vessels (9, 28) is performed by ozone circulation. 
Postupak prema zahtjevu 1, naznačen time, da se miješanje u prvoj i drugoj posudi reaktora (9, 28) provodi cirkulacijom ozona.
Process according to claim 1, wherein disinfection of waste water in the first and second reactor vessels (9, 28) is performed by UV lamp (16), (37) and (79) strength 9 kW in duration from 1 to 20 min. 
Postupak prema zahtjevu 1, naznačen time, da se dezinficiranje otpadne vode u prvoj i drugoj posudi reaktora (9, 28) vrši UV lampom (16), (37) i (79) snage 9 kW u trajanju od 1 do 20 min.
Process according to claim 1, wherein mixing in the first and second reactor vessels (9, 28) is performed by compressed air circulation. 
Postupak prema zahtjevu 1, naznačen time, da se miješanje u prvoj i drugoj posudi reaktora (9, 28) provodi pomoću cirkulacije komprimiranog zraka.
Process according to claim 1, wherein mixing in the first and second reactor vessels (9, 28) is performed by oxygen circulation. 
Postupak prema zahtjevu 1, naznačen time, da se miješanje u prvoj i drugoj posudi reaktora (9, 28) provodi cirkulacijom kisika.
Process according to claim 1, wherein electrochemical phase of water treatment in the first reaction vessel (9) with reactor electrode made of fixed inox plates lasts from 5 to 180 minutes. 
Postupak prema patentnom zahtjevu 1, naznačen time, da elektrokemijska faza obrade vode u prvoj reakcijskoj posudi (9) s reaktorskom elektrodom načinjenom od fiksnih inox ploča traje od 5 do 180 minuta.
Process according to claim 1, wherein electrochemical phase of water treatment in the second reaction vessel (28) with reactor electrodes made of fixed steel plates lasts from 5 to 180 minutes. 
Postupak prema zahtjevu 1, naznačen time, da elektrokemijska faza obrade vode u drugoj reaktorskoj posudi (28) s reaktorskim elektrodama izrađenih od nepomičnih čeličnih ploča traje od 5 do 180 minuta.
Process according to claim 1, wherein electrochemical phase of water treatment in the second reaction vessel (28) with additional reactor electrode set made of fixed aluminium plates lasts from 5 to 180 minutes. 
Postupak prema zahtjevu 1, naznačen time, da elektrokemijska faza obrade vode u drugoj reaktorskoj posudi (28) s dodatnim setom reaktorskih elektroda izrađenih od nepomičnih aluminijskih ploča traje od 5 do 180 minuta.
Device for electrochemical treatment and separation of heavy metals from industrial wastewater and drinking water, indicating that it consists of: 
Uređaj za elektrokemijsku obradu i odvajanje teških metala iz industrijske otpadne vode i pitke vode, naznačen time, da se sastoji od:
a first water pump (2) for pumping wastewater into a water preparation tank (3); 
prve vodene pumpe (2) za pumpanje otpadne vode u spremnik za pripremu vode;
ozone generator (12), ozone pump (11) for pumping ozone into bottom of first and second reactor vessel (9, 28), which provides destruction of organic matter and pathogens through ozonolysis, disinfection and mixing of water in both first and second reactor vessels (9, 28); 
generatora ozona (12), pumpe za ozon (11) za upumpavanje ozona na dno prve i druge reaktorske posude (9, 28), čime se provodi razgradnja organske tvari i patogena kroz ozoniranje, dezinfekciju i miješanje vode u prvoj i drugoj reaktorskoj posudi (9, 28);
Device according to claim 13, wherein direct current in the same treatment phase in the reactor vessel is suppliable parallel to both steel and aluminium reactor electrode set. 
Uređaj u skladu sa zahtjevom 13, naznačen time, da se istosmjerna struja u istoj fazi obrade u posudi reaktora dovodi istovremeno paralelno i na čelične i na aluminijske reaktorske elektrode.
Use of biopolymers for removing phosphorus from wastewater, wherein the biopolymers are isolated using the following method: 
Uporaba biopolimera za odstranjivanje fosfora iz otpadne vode, naznačena time, da se biopolimeri izoliraju uporabom sljedećeg postupka:
disrupting the bacterial cell walls of bacteria present in sewage sludge by at least 75% to release the intracellular contents of the bacterial cells; and ii) separating the biopolymers from any contaminants present. 
uništavanje stijenki bakterijskih stanica od bakterija koje su prisutne u otpadnom mulju za najmanje 75%, u svrhu oslobađanja unutarstaničnog sadržaja bakterijskih stanica; i ii) odvajanje biopolimera iz bilo kojih kontaminanata koji su prisutni.
removing extracellular polymeric substances (EPS) from the bacterial cells in the sewage sludge prior to disrupting the bacterial cell walls. 
odstranjivanje izvanstaničnih polimernih tvari (EPS) iz bakterijskih stanica u otpadnom mulju prije uništavanja stijenki bakterijskih stanica.
Use according to claim 3, wherein the soluble biopolymers precipitated comprise nucleic acids. 
Uporaba prema zahtjevu 3, naznačena time, da nataloženi topivi biopolimeri obuhvaćaju nukleinske kiseline.
Use according to claim 1 or 2 wherein the cell lysate is anaerobically digested and peptidoglycan present in the cell lysate is separated and isolated. 
Uporaba prema zahtjevu 1 ili 2, naznačena time, da se stanični lizat razgrađuje anaerobno te se peptidoglikan koji je prisutan u staničnom lizatu odvaja i izolira.
Use according to any of claims 1 to 11 wherein the biopolymers are treated before, during or post the precipitation step with one or more chemicals. 
Uporaba prema bilo kojem od zahtjeva 1 do 11, naznačena time, da se biopolimeri obrađuju s jednom ili više kemikalija, prije, za vrijeme ili nakon koraka taloženja.
The pharmaceutical combination according to claim 3, wherein components (i) and (ii) are formulated for simultaneous administration. 
Farmaceutska kombinacija prema patentnom zahtjevu 3, naznačena time, što su spoj (i) i drugo antifungalno sredstvo (ii) formulirani za odvojenu, simultanu ili sukcesivnu primjenu.
The pharmaceutical combination according to claim 3, wherein the second antifungal agent is selected from the group consisting of azoles, polyenes, purine nucleotide inhibitors, pyrimidine nucleotide inhibitors, mannan inhibitors, protein elongation factor inhibitors, echinocandins, allylamines, anti-HSP90 antibodies, bactericidal/permeability inducing protein products, polyoxins, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborale, 5-chloro-1,3-dihydro-1-hydroxy-2,1-benzoxaborale, icofungipen, VT116 and SCY078. 
Farmaceutska kombinacija prema patentnom zahtjevu 3 ili patentnom zahtjevu 4, naznačena time, što je drugo antifungalno sredstvo odabrano iz skupine koja se sastoji od azola, poliena, inhibitora purinskog nukleotida, inhibitora pirimidinskog nukleotida, inhibitora manana, inhibitora faktora proteinske elongacije, ehinokandina, alialamina, anti-HSP90 antitijela, proteinskih proizvoda ili polioksina koji izazivaju baktericidnost/propusnost ili jednog od spojeva 5-fluoro-1,3-dihidro-1-hidroksi-2,1-benzoksaboral, 5-kloro-1,3-dihidro-1-hidroksi-2,1-benzoksaboral, ikofungipen, VT116 ili SCY078.
A method of controlling a fungal disease in a plant, which method comprises applying to the locus of the plant: 
Način za kontroliranje gljivičnog oboljenja kod biljke, koji se sastoji od primjene na lokusu biljke spoja koji je:
fastening in advance each waterproof panel (14; 14A) to the bottom (11) and/or to the side banks (12) of the canal or water basin (10) during laying; 
pričvršćivanje svake vodonepropusne ploče (14; 14A) unaprijed na dno (11) i / ili na bočne strane (12) kanala ili vodenog bazena (10) tijekom polaganja;
The method for installation and laying down of a waterproof liner according to claim 1 characterised by performing the fastening step of each panel (14; 14A), and the watertight connection of the intermediate connecting device (28; 44, 45) during underwater laying of each waterproof panel (14; 14A) into the canal or water basin (10). 
Postupak ugradnje i polaganje vodonepropusne obloge u skladu s patentnim zahtjevom 1, naznačen time, da se provodi korak pričvršćivanja svake ploče (14; 14A) i vodonepropusno spajanje srednjeg spojnog uređaja (28; 44, 45) tijekom polaganja svake vodonepropusne ploče (14; 14A) u kanal ili vodeni bazen (10).
The method for installation and laying of a waterproof liner according to claim 9, characterised by configuring the bottom waterproof membrane (16) and/or the upper waterproof membrane (17) with synthetic material having a permeability coefficient (K) equal to or lower than 10-10cm/s. 
Postupak ugradnje i polaganja vodonepropusne obloge u skladu s patentnim zahtjevom 9, naznačen time, da se prva vodonepropusna membrana (16) i / ili druga vodonepropusna membrana (17) oblikuju od sintetskog materijala koji ima koeficijent propusnosti (K) jednak ili niži od 10-10 cm / s.
The method for installation and laying of a waterproof liner according to claim 10, characterised by configuring the first waterproof membrane (16) and/or the second waterproof membrane (17) with synthetic material having a permeability coefficient (K) equal to or lower than 10-10 cm/s. 
Postupak ugradnje i polaganja vodonepropusne obloge u skladu s patentnim zahtjevom 10, naznačen time, da se prva vodonepropusna membrana (16) i / ili druga vodonepropusna membrana (17) oblikuju od sintetskog materijala koji ima koeficijent propusnosti (K) jednak ili niži od 10-10 cm / s.
A waterproof liner for a canal or water basin (10) suitable to be installed and laid down by the method of claim 1, characterized in that the liner comprises: 
Vodonepropusna obloga za kanal ili vodeni bazen (10) pogodna za ugradnju i postavljanje postupkom u skladu s patentnim zahtjevom 1, naznačena time, da obloga sadržava:
each panel (14; 14A) comprising at least an opening for injecting cementitious mixture (30) for ballasting and frictionally anchoring each panel (14; 14A) to the bottom or the side banks of a canal or water basin. 
svaka ploča (14; 14A) sadržava barem jedan otvor za ubrizgavanje cementne smjese (30) za balastiranje i frikcijsko sidrenje svake ploče (14; 14A) na dno ili bočne strane kanala ili vodenog bazena.
The waterproof liner according to claim 23, characterised in that the expandable watertight device (45) comprises a material which expands in contact with water. 
Vodonepropusna obloga u skladu s patentnim zahtjevom 23, naznačena time, da ekspandirajući vodonepropusni uređaj (45) sadržava materijal koji se širi u dodiru s vodom.
The waterproof liner according to claim 24, characterised in that the expandable watertight device is positioned between two side spongy members (44.1, 44.2). 
Vodonepropusna obloga u skladu s patentnim zahtjevom 24, naznačena time, da se ekspandirajući vodonepropusni uređaj nalazi između dva bočna spužvasta elementa (44.1, 44.2).
The waterproof liner according to claim 25, characterised by comprising a first water leakage detecting chamber (46.1), respectively a second chamber (46.2) for injecting a sealing-material, said first and second chamber being disposed between the expandable watertight member (45) and the side spongy members (44.1, 44.2). 
Vodonepropusna obloga u skladu s patentnim zahtjevom 25, naznačena time, da sadržava prvu komoru za otkrivanje propuštanja vode (46.1), odnosno drugu komoru (46.2) za ubrizgavanje brtvenog materijala, pri čemu se navedena prva i druga komora raspoređene između ekspandirajućeg vodonepropusnog elementa (45) i bočnih spužvastih elemenata (44.1, 44.2).
A waterproof panel (14,14A) suitable for installation and laying a waterproof liner for canals and water basins (10) according to one or more of claims 18 to 26, characterised in that the panel (14; 14A) is configured as a panel provided with a tubular chamber (18) comprising: 
Vodonepropusna ploča (14, 14A) pogodna za ugradnju i postavljanje vodonepropusne obloge za kanale i vodene bazene (10) u skladu s jednim ili više patentnih zahtjeva od 18 do 26, naznačena time, da je ploča (14; 14A) oblikovana kao ploča s cijevnom komorom (18) koja sadržava:
at least one waterproof membrane (16) made of geosynthetic material, having side edges extending in a longitudinal direction of the panel (14); 
najmanje jednu vodonepropusnu membranu (16) izrađenu od geosintetskog materijala, s bočnim rubovima koji se protežu u uzdužnom smjeru ploče (14);
The waterproof panel (14; 14A) according to claim 28 or 29, characterised in that at least one of the waterproof membranes (16, 17) is made of a geosynthetic material. 
Vodonepropusna ploča (14; 14A) u skladu s patentnim zahtjevom 28 ili 29, naznačena time, da je najmanje jedna od vodonepropusnih membrana (16, 17) načinjena od geosintetskog materijala.
The footing according to claim 1, characterized in that said uprights (3) comprise tubular profiled elements and/or elements made of bent sheet metal. 
Postolje u skladu s patentnim zahtjevom 1, naznačeno time, da navedeni uspravni držači (3) sadržavaju cjevaste profilirane elemente i / ili elemente izrađene od savijenog lima.
The footing according to claim 3, characterized in that said base element (5) comprises elements made of bent sheet metal and/or tubular profiled elements. 
Postolje u skladu s patentnim zahtjevom 3, naznačeno time, da navedeni osnovni element (5) sadržava elemente izrađene od savijenog lima i / ili cjevastog profiliranog elementa.
The footing according to claim 1, characterized in that it comprises a front element (13) that can be associated with the front side of said supporting structure (2) and is provided with a box-like structure, constituted by a molded covering made of technopolymer mounted on a plate and ergonomically contoured in order to contain instruments for the control and actuation of the machine. 
Postolje u skladu s patentnim zahtjevom 1, naznačeno time, da obuhvaća prednji element (13) koji se može povezati s prednjom stranom navedene nosive konstrukcije (2) i ima kutijastu strukturu koja je načinjena od oblikovanog poklopca izrađenog od tehnopolimera montiranog na ploči i ergonomski oblikovana kako bi sadržavao instrumente za upravljanje i pokretanje stroja.
The footing according to claim 8, characterized in that it comprises elements (19) for the snap fixing of at least part of said covering panels (16, 17, 18a, 18b) to said supporting structure (2). 
Postolje u skladu s patentnim zahtjevom 8, naznačeno time, da obuhvaća elemente (19) za uskočno pričvršćivanje barem dijela navedenih pokrovnih ploča (16, 17, 18a, 18b) na navedenu nosivu konstrukciju (2).
- R2 is selected from the group consisting of: 
R2 je odabran iz skupine koja obuhvaća: i
is a saturated or unsaturated straight chain or branched optionally substituted aliphatic carbon chain. 
je zasićen ili nezasićen ravan lanac ili razgranat opcijski supstituiran alifatni lanac ugljika.
The compound of claim 1, wherein R1-R2 is 
Spoj sukladno patentnom zahtjevu 1, naznačeno time R1-R2 da je
The compound of claim 1 or claim 2, wherein R' is H. 
Spoj sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačeno time da R’ je H.
The compound of claim 5, wherein R23 is -CH3. 
Spoj sukladno patentnom zahtjevu 5, naznačeno time, da R23 je -CH3.
comprises an optionally substituted C1-C3 alkyl; 
obuhvaća izborno supstituiran C1-C3 alkil;
is substituted with an amino; 
je supstituiran s nekim amino;
reacting cyclosporin-A (CsA) with a basic lithium alkylamide, in the presence of a suitable solvent, followed by reaction with a suitable electrophile to generate a compound of Formula 1: 
dovođenja u reakciju ciklosporina-A (CsA) s baznim litij alkilamidom, u prisutnosti odgovarajućeg otapala, nakon čega je uslijedila reakcija s odgovarajućim elektrofilom da bi se generirao spoj iz Formule 1:
reacting the compound of Formula 1 with AC2O in the presence of a suitable solvent to form a compound of Formula 2A: 
Reakcija spoja Formule 1 s AC2O u prisutnosti odgovarajućeg otapala da bi se stvorio spoj sukladno Formuli 2A:
reacting the compound of Formula 3A with an electrophile to form a compound of Formula 4A: 
Reakcija spoja sukladno Formuli 3A s elektrofilom da bi se stvorio spoj sukladno Formuli 4A:
optionally deacylating the compound of Formula 4A. 
izborno deacilacija spoja sukladno Formuli 4A.
The process of claim 11, wherein said preparation of the compound of Formula L comprises the addition of an excess of LiCI in said suitable solvent in step 1) to form predominantly the L-epimer of the compound of Formula L, or said preparation of the compound of Formula L is carried out in the absence of LiCI to form predominantly the D-epimer of the compound of Formula L. 
Postupak sukladno patentnom zahtjevu 11, naznačeno time, da navedeno dobivanje spoja od Formule L obuhvaća dodavanje viška LiCI u navedenom odgovarajućem otapalu u koraku 1) da bi se oblikovao pretežno L epimer spoja od Formule L, ili navedeno dobivanje spoja od Formule L je izvedeno u odsutnosti LiCI da bi se oblikovao pretežito D epimer spoja od Formule L.